Schott opens new China pharma packaging plant
This article was originally published in Scrip
Schott has opened a new plant for the production of glass pharmaceutical packaging on its existing site in Suzhou, China. The facility is the first of its kind to be set up in the country by a foreign firm, and will supply primary containers to both domestic and multinational companies. The Chinese market for glass packaging is still dominated by low price products, but demand for Schott's high quality lines is expected to grow along with the overall pharma industry, the German group notes. The 2,500m2 facility has 50 employees and a current annual capacity of more than 100 million ampoules and vials, which can be increased if required.
You may also be interested in...
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.